Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies

Adoptive cell therapies with chimeric antigen receptor (CAR) engineered T cells (CAR-T) and immune checkpoint inhibition (ICI)-based cancer immunotherapies have lately shown remarkable success in certain tumor types. CAR-T cell-based therapies targeting CD19 can now induce durable remissions as well...

Descripción completa

Detalles Bibliográficos
Autores principales: Hegde, Upendra P., Mukherji, Bijay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579167/
https://www.ncbi.nlm.nih.gov/pubmed/28497159
http://dx.doi.org/10.1007/s00262-017-2007-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579167/
https://www.ncbi.nlm.nih.gov/pubmed/28497159
http://dx.doi.org/10.1007/s00262-017-2007-x

Ejemplares similares